💊 Ticagrelor

Ticagrelor is an antiplatelet agent, specifically a direct-acting, reversible P2Y12 receptor antagonist. It belongs to the cyclopentyltriazolopyrimidine class.

Unlike clopidogrel, ticagrelor is not a prodrug and does not require hepatic activation. It directly and reversibly binds to the P2Y12 ADP receptor on platelets, preventing ADP-mediated platelet activation and aggregation. Its action is rapid in onset and offset due to its reversible binding.

Ticagrelor is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS), including unstable angina, NSTEMI, or STEMI. It is typically used in combination with aspirin as dual antiplatelet therapy (DAPT) for a specified duration, often following percutaneous coronary intervention (PCI).

Absolute contraindications include active pathological bleeding, such as peptic ulcer or intracranial haemorrhage. A history of intracranial haemorrhage is also a contraindication. Severe hepatic impairment is another contraindication. Concomitant use with strong CYP3A4 inhibitors should be avoided.

The most common adverse effect is bleeding, which can range from minor to life-threatening. Dyspnoea (shortness of breath) is also frequently reported, usually mild and transient. Other effects include bradycardia, headache, and gastrointestinal disturbances. Hyperuricaemia and increased creatinine levels can occur.

No routine blood monitoring is typically required for ticagrelor. Patients should be closely monitored for signs of bleeding, especially during the initial treatment period. Renal function and uric acid levels may be monitored in patients with pre-existing conditions or if symptoms suggest impairment.

When prescribing, always check for active bleeding, a history of intracranial haemorrhage, and severe hepatic impairment. Be aware of drug interactions, particularly with strong CYP3A4 inhibitors/inducers, and other antiplatelet agents or anticoagulants. Counsel patients on the increased risk of bleeding and to report any unusual bruising, bleeding, or shortness of breath.

Ticagrelor's direct and reversible P2Y12 antagonism is a key differentiating factor. It is a preferred antiplatelet in ACS due to its rapid onset and more consistent antiplatelet effect compared to clopidogrel. Remember the common side effect of dyspnoea and the increased bleeding risk. It is crucial to co-administer with low-dose aspirin.

SBA questions often highlight ticagrelor's direct and reversible P2Y12 inhibition, contrasting it with clopidogrel's prodrug nature. Its use in ACS as part of DAPT and the duration of therapy are common themes. Questions might also focus on its unique side effects, particularly dyspnoea and bradycardia, and its contraindications, especially active bleeding or history of intracranial haemorrhage.